Patent · US Active

Crystal form a of (5-amino-8-(2-methyl-6-(trifluoromethyl)pyridin-4-yl)-7-phenyl-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)methanol (compound 1)

US11649239B2 · kind B2 · utility

0Cited by

2References

12Claims

0Family size

Assignee

Medshine Discovery Inc. · CN

Inventors

Kevin X. Chen · Edison, US
Yanxin YU · Shanghai, CN
Xinde Chen · Shanghai, CN
Li Zhang · New Milford, US
Zhaoguo Chen · Shanghai, CN
Cheng Xie · Shanghai, CN

Key dates

Filing date	Apr 28, 2019
Grant date	May 16, 2023
Priority date	—
Expiry date	Feb 12, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/13
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed in the present invention are a crystal form of a [1,2,4]triazolo[1,5-c]pyrimidine compound and a preparation method thereof. Further disclosed is a use of the crystal form in the preparation of a medicament for treating A2A receptor related diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.